Chemoprevention in hereditary colorectal cancer syndromes

Reagan M. Barnett; Ester Borras; N. Jewel Samadder; Eduardo Vilar

doi:10.1007/978-3-319-74259-5_22

Chemoprevention in hereditary colorectal cancer syndromes

Reagan M. Barnett, Ester Borras, N. Jewel Samadder, Eduardo Vilar

Gastroenterology and Hepatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Patients and families diagnosed with hereditary colorectal cancer syndromes present with an accelerated carcinogenesis. In this scenario, screening measures and preventive interventions play a crucial role in modulating the cancer risk by decreasing its incidence and mortality. In this chapter we will provide an overview of the clinical evidence of chemopreventive interventions developed in Familial Adenomatous Polyposis and Lynch Syndrome. Specifically, we will present the use of non-steroidal anti-inflammatory drugs (NSAIDs), which have been the most commonly studied agents in this field. Finally, we will discuss the latest clinical trials deploying targeted agents and modern NSAIDs in the context of prevention of hereditary colorectal cancer syndromes.

Original language	English (US)
Title of host publication	Hereditary Colorectal Cancer
Subtitle of host publication	Genetic Basis and Clinical Implications
Publisher	Springer International Publishing
Pages	349-365
Number of pages	17
ISBN (Electronic)	9783319742595
ISBN (Print)	9783319742588
DOIs	https://doi.org/10.1007/978-3-319-74259-5_22
State	Published - Jan 1 2018

Keywords

Aspirin
Chemoprevention
Cox-2 inhibitors
Familial adenomatous polyposis
Hereditary colorectal cancer syndromes
Lynch syndrome
Nonsteroidal anti-inflammatory drugs

ASJC Scopus subject areas

General Medicine
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1007/978-3-319-74259-5_22

Cite this

@inbook{8c5160bde21749ab9eb943f29ba4d163,

title = "Chemoprevention in hereditary colorectal cancer syndromes",

abstract = "Patients and families diagnosed with hereditary colorectal cancer syndromes present with an accelerated carcinogenesis. In this scenario, screening measures and preventive interventions play a crucial role in modulating the cancer risk by decreasing its incidence and mortality. In this chapter we will provide an overview of the clinical evidence of chemopreventive interventions developed in Familial Adenomatous Polyposis and Lynch Syndrome. Specifically, we will present the use of non-steroidal anti-inflammatory drugs (NSAIDs), which have been the most commonly studied agents in this field. Finally, we will discuss the latest clinical trials deploying targeted agents and modern NSAIDs in the context of prevention of hereditary colorectal cancer syndromes.",

keywords = "Aspirin, Chemoprevention, Cox-2 inhibitors, Familial adenomatous polyposis, Hereditary colorectal cancer syndromes, Lynch syndrome, Nonsteroidal anti-inflammatory drugs",

author = "Barnett, {Reagan M.} and Ester Borras and {Jewel Samadder}, N. and Eduardo Vilar",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing AG, part of Springer Nature 2018.",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/978-3-319-74259-5_22",

language = "English (US)",

isbn = "9783319742588",

pages = "349--365",

booktitle = "Hereditary Colorectal Cancer",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Chemoprevention in hereditary colorectal cancer syndromes

AU - Barnett, Reagan M.

AU - Borras, Ester

AU - Jewel Samadder, N.

AU - Vilar, Eduardo

N1 - Publisher Copyright: © Springer International Publishing AG, part of Springer Nature 2018.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients and families diagnosed with hereditary colorectal cancer syndromes present with an accelerated carcinogenesis. In this scenario, screening measures and preventive interventions play a crucial role in modulating the cancer risk by decreasing its incidence and mortality. In this chapter we will provide an overview of the clinical evidence of chemopreventive interventions developed in Familial Adenomatous Polyposis and Lynch Syndrome. Specifically, we will present the use of non-steroidal anti-inflammatory drugs (NSAIDs), which have been the most commonly studied agents in this field. Finally, we will discuss the latest clinical trials deploying targeted agents and modern NSAIDs in the context of prevention of hereditary colorectal cancer syndromes.

AB - Patients and families diagnosed with hereditary colorectal cancer syndromes present with an accelerated carcinogenesis. In this scenario, screening measures and preventive interventions play a crucial role in modulating the cancer risk by decreasing its incidence and mortality. In this chapter we will provide an overview of the clinical evidence of chemopreventive interventions developed in Familial Adenomatous Polyposis and Lynch Syndrome. Specifically, we will present the use of non-steroidal anti-inflammatory drugs (NSAIDs), which have been the most commonly studied agents in this field. Finally, we will discuss the latest clinical trials deploying targeted agents and modern NSAIDs in the context of prevention of hereditary colorectal cancer syndromes.

KW - Aspirin

KW - Chemoprevention

KW - Cox-2 inhibitors

KW - Familial adenomatous polyposis

KW - Hereditary colorectal cancer syndromes

KW - Lynch syndrome

KW - Nonsteroidal anti-inflammatory drugs

UR - http://www.scopus.com/inward/record.url?scp=85086980289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086980289&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-74259-5_22

DO - 10.1007/978-3-319-74259-5_22

M3 - Chapter

AN - SCOPUS:85086980289

SN - 9783319742588

SP - 349

EP - 365

BT - Hereditary Colorectal Cancer

PB - Springer International Publishing

ER -

Chemoprevention in hereditary colorectal cancer syndromes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this